November 22, 2022 05:33 AM EST

Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

Amber Tong

GSK is pulling its BCMA-targeting drug from the US market, ending a short, two-year run for a high-profile product that, among other things, was hailed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

Amber Tong

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations

Days af­ter re­port­ing PhI­II fail­ure, GSK pulls BC­MA drug from US mar­ket — but it's not giv­ing up en­tire­ly yet

Amber Tong

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Sofinnova outlines $550M fund after IPOs and M&A deals

WuXi AppTec will sell cell and gene therapy business to private equity firm

CMS explains what went into its first round of drug price negotiations